Via FierceBiotech, the impact of the Russian invasion on global drug development:
Russia's invasion of Ukraine is likely to impact millions of people, not just in the Eastern European nation but around the world as drug developers might face delays in clinical trials conducted in Kyiv and elsewhere.
One biotech, in particular, called out the geopolitical tensions as possible cause for concern. Karuna Therapeutics warned today that timelines for its second phase 3 study in schizophrenia, dubbed EMERGENT-3, are uncertain because 10 of the 19 trial sites are in Ukraine.
At the other end of the drug pipeline, this tweet from Ukraine-based chemistry services company Enamine:
Today, Russia started a full-scale war against Ukraine. We believe in our soldiers and we stay strong. We have to postpone our services till Monday, February 28. We hope you take this short-term disruption with understanding.
I cannot imagine what kind of disruption is going on in Ukraine, and what kind of disruption the future holds. Best wishes to the people of Ukraine.